- Home
- CRVO vs IMUX Comparison
CRVO vs IMUX Comparison
Compare CRVO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- IMUX
- Stock Information
- Founded
- CRVO 2001
- IMUX 2016
- Country
- CRVO United States
- IMUX United States
- Employees
- CRVO N/A
- IMUX N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- CRVO Health Care
- IMUX Health Care
- Exchange
- CRVO Nasdaq
- IMUX Nasdaq
- Market Cap
- CRVO 95.4M
- IMUX 94.9M
- IPO Year
- CRVO N/A
- IMUX N/A
- Fundamental
- Price
- CRVO $8.90
- IMUX $1.02
- Analyst Decision
- CRVO Strong Buy
- IMUX Strong Buy
- Analyst Count
- CRVO 8
- IMUX 6
- Target Price
- CRVO $25.43
- IMUX $13.20
- AVG Volume (30 Days)
- CRVO 455.4K
- IMUX 1.3M
- Earning Date
- CRVO 05-20-2025
- IMUX 05-20-2025
- Dividend Yield
- CRVO N/A
- IMUX N/A
- EPS Growth
- CRVO N/A
- IMUX N/A
- EPS
- CRVO N/A
- IMUX N/A
- Revenue
- CRVO $9,737,974.00
- IMUX N/A
- Revenue This Year
- CRVO N/A
- IMUX N/A
- Revenue Next Year
- CRVO N/A
- IMUX N/A
- P/E Ratio
- CRVO N/A
- IMUX N/A
- Revenue Growth
- CRVO 36.29
- IMUX N/A
- 52 Week Low
- CRVO $1.80
- IMUX $0.83
- 52 Week High
- CRVO $25.69
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- CRVO 48.85
- IMUX 47.20
- Support Level
- CRVO $8.40
- IMUX $0.96
- Resistance Level
- CRVO $11.79
- IMUX $1.22
- Average True Range (ATR)
- CRVO 0.96
- IMUX 0.12
- MACD
- CRVO -0.15
- IMUX -0.00
- Stochastic Oscillator
- CRVO 14.75
- IMUX 19.44
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.